Home>FAQ

FAQ

Q1: What factors affect knockdown efficiency?

Q2: How to verify efficiency?

Q3: For the siRNA in vivo transfection reagent, the product Q&A mentions non-targeting, most obvious in lung and liver. The customer's target organ is the spleen. Do you have relevant data for this?

Q4: Is your transfection reagent GMP grade?

Q5: What are the differences between "RNA in vitro transfection reagents" and "RNA in vivo transfection reagents"?

Q6: What is the difference between the [RNA In Vitro Transfection Reagent] and the [RNA In Vivo Transfection Reagent]?

Q7: Can both RNA transfection reagents be used for RNA and DNA co-transfection?

Q8: May I ask why glucose solution is needed for dilution? Can glucose diluent be omitted to reduce the injection volume?

Q9: Why is glucose solution needed for dilution? To reduce injection volume, can the glucose diluent be omitted?

Q10: Can the RNA and transfection reagent complex be diluted with other reagents?

Q11: Can the RNA and transfection reagent complex be diluted with other reagents?

Q12: Are the purification methods of siRNA and miRNA different from those of mRNA?

Q13: Are the purification methods for siRNA and miRNA different from mRNA purification?

Q14: Must the RNA used be purified by PAGE and HPLC methods? Are there any other purification methods for siRNA and miRNA?

Q15: Must the RNA used be purified by PAGE and HPLC? Are there other purification methods for siRNA and miRNA?

Q16: Does this in vivo transfection reagent have bone tissue targeting?

« »